Geode Capital Management LLC raised its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 16.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 276,974 shares of the biotechnology company’s stock after buying an additional 39,934 shares during the period. Geode Capital Management LLC’s holdings in Anavex Life Sciences Corp. were worth $1,589,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of AVXL. JPMorgan Chase & Co. acquired a new position in shares of Anavex Life Sciences Corp. during the first quarter valued at $105,000. American International Group Inc. raised its position in shares of Anavex Life Sciences Corp. by 7.1% in the first quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 1,329 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Anavex Life Sciences Corp. by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 5,826 shares during the last quarter. State Street Corp raised its position in shares of Anavex Life Sciences Corp. by 27.2% in the fourth quarter. State Street Corp now owns 391,065 shares of the biotechnology company’s stock valued at $1,549,000 after buying an additional 83,716 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Anavex Life Sciences Corp. by 13.1% in the first quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock valued at $8,528,000 after buying an additional 171,577 shares during the last quarter. 24.41% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 0.45% during trading on Friday, hitting $4.46. 104,658 shares of the stock were exchanged. Anavex Life Sciences Corp. has a 1-year low of $2.43 and a 1-year high of $6.64. The firm’s 50 day moving average price is $4.28 and its 200-day moving average price is $5.37. The stock’s market cap is $188.09 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, analysts anticipate that Anavex Life Sciences Corp. will post ($0.38) EPS for the current year.

WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/01/geode-capital-management-llc-acquires-39934-shares-of-anavex-life-sciences-corp-avxl.html.

Several brokerages recently weighed in on AVXL. Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Noble Financial reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Wednesday, August 9th. ValuEngine raised shares of Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd. Finally, Maxim Group set a $15.00 price target on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a research report on Monday, August 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $11.44.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.